What we're reading, December 14, 2016: many Obamacare enrollees voted for Donald Trump expecting him to fix, not repeal, the law; President Barack Obama signs 21st Century Cures Act into law; Ohio Governor John Kasich vetoes one abortion bill, signs another.
People who have enrolled for healthcare insurance through the Affordable Care Act (ACA) and voted for Donald Trump did so because they expected him to fix, not repeal, the law. According to Vox’s Sarah Kliff, who spent time in Kentucky interviewing Trump supporters, people were frustrated with the rising cost of premiums and deductibles and the idea that other people were getting better, cheaper benefits. They all believed that Trump would fix the problems they saw with the ACA and that he wouldn’t really repeal the law.
President Barack Obama has signed the 21st Century Cures Act into law. The bill invests $1.8 billion in Vice President Joe Biden’s Cancer Moonshot program and includes an $6.3 billion in new spending overall in the next 10 years. While the bill represents a rare example of bipartisanship, patient advocacy groups remain opposed to it, reported the AP. They believe the bill weakens FDA oversight. At the signing, Obama touted the benefits of the ACA in the hope that Congress will continue its bipartisan work and keep the bill.
In Ohio, Governor John Kasich vetoed one abortion bill only to sign into law another, less restrictive abortion bill. According to The Washington Post, Kasich vetoed the controversial “heartbeat bill” that would ban abortion as early as 6 weeks—before most women know they are pregnant. However, he did sign a bill that banned the procedure at 20 weeks. The newly signed law conflicts with previous Supreme Court decisions, which tend to uphold abortion rights until around 24 weeks.
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More